ReShape Lifesciences Inc. (NASDAQ:RSLS) Short Interest Update

ReShape Lifesciences Inc. (NASDAQ:RSLS) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 1,720,000 shares, an increase of 272.0% from the June 30th total of 462,400 shares. Approximately 6.6% of the shares of the stock are short sold. Based on an average daily volume of 6,270,000 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reissued a “hold” rating on shares of ReShape Lifesciences in a report on Wednesday, July 17th.

ReShape Lifesciences Stock Up 3.7 %

Shares of RSLS traded up $0.01 during mid-day trading on Thursday, hitting $0.21. 240,585 shares of the stock were exchanged, compared to its average volume of 3,281,876. ReShape Lifesciences has a 52-week low of $0.14 and a 52-week high of $1.66. The firm has a 50-day moving average of $0.21 and a two-hundred day moving average of $0.19.

ReShape Lifesciences (NASDAQ:RSLS) last issued its quarterly earnings data on Wednesday, May 15th. The medical device company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $1.94 million for the quarter. ReShape Lifesciences had a negative return on equity of 207.78% and a negative net margin of 130.99%.

About ReShape Lifesciences

ReShape Lifesciences Inc provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus.